Clinical study of prostatic cancers with a PSA level of more than 100 ng/ml at the first hospital visit

We report the results of a clinical study of 77 patients with prostatic cancer who had a PSA level of more than 100 ng/ml at the first hospital visit between 2001 and 2005. The PSA levels ranged from 107 ng/ml to 14,455 ng/ml (median 301 ng/ml). Most of the patients had symptoms due to prostatic cancer, a high Gleason score and advanced clinical stage. Almost all the patients were treated with androgen deprivation therapy. However, many patients had PSA failure and their prognosis was poor, nevertheless, long-term PSA failure-free survival was achieved in some patients. We need to ascertain the precise prognostic marker to androgen deprivation therapy.